Summary
Thermo Fisher Scientific Inc. (TMO) filed its 2014 annual report on Form 10-K, detailing a year marked by significant strategic moves and operational performance. The company successfully completed the acquisition of Life Technologies Corporation in February 2014, a transformative event that substantially expanded its scale and capabilities, particularly within the Life Sciences Solutions segment. This acquisition drove a significant increase in revenue and assets, alongside related integration costs and increased debt. Financially, TMO demonstrated revenue growth in 2014, largely attributable to the Life Technologies acquisition and incremental gains from business divestitures, partially offset by unfavorable currency translation. The company managed its expenses effectively, leading to an increase in operating income and operating income margin compared to the prior year. Despite the integration complexities and increased financial leverage from the acquisition, TMO's management expressed confidence in its liquidity and ability to meet future cash requirements through operational cash flow and existing credit facilities.
Financial Highlights
59 data points| Revenue | $16.89B |
| Cost of Revenue | $7.93B |
| Gross Profit | $8.95B |
| R&D Expenses | $691.10M |
| SG&A Expenses | $4.90B |
| Operating Expenses | $14.39B |
| Operating Income | $2.50B |
| Interest Expense | $479.90M |
| Net Income | $1.89B |
| EPS (Basic) | $4.76 |
| EPS (Diluted) | $4.71 |
| Shares Outstanding (Basic) | 398.20M |
| Shares Outstanding (Diluted) | 402.30M |
Key Highlights
- 1Completed the transformative acquisition of Life Technologies Corporation in February 2014 for $15.3 billion, significantly expanding its Life Sciences Solutions segment.
- 2Reported 2014 revenues of $16.89 billion, a substantial increase driven by acquisitions, with organic revenue growth of 4% excluding currency impacts and divestitures.
- 3Achieved an operating income of $2.50 billion in 2014, with an operating margin of 14.8%, up from $1.61 billion and 12.3% in 2013, benefiting from business gains and Life Technologies' inclusion.
- 4Divested several businesses, including legacy sera and media, gene modulation, magnetic beads, and Cole-Parmer specialty channel, resulting in pre-tax gains of approximately $761 million and $134 million, respectively.
- 5Maintained consistent quarterly cash dividends of $0.15 per share throughout 2014 and 2013.
- 6As of December 31, 2014, the company had approximately $14.56 billion in outstanding indebtedness, reflecting the financing of the Life Technologies acquisition.
- 7Invested $691 million in research and development in 2014, emphasizing continued innovation and product development to maintain competitive positioning.